CoChat
Sign Up
Cited by 220Multiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersGlaucoma and retinal disorders

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD

Watanabe, Mitsuru, Nakamura, Yuri, Michalak, Zuzanna, Isobe, Noriko, Barro, Christian, Leppert, David, Matsushita, Takuya, Hayashi, Fumie, Yamasaki, Ryo, Kuhle, Jens, Kira, Jun-ichi·2019·Neurology
DOI 10.1212/wnl.0000000000008160
Open this paper in CoChat — free account

Abstract

OBJECTIVE: To test the hypothesis that serum levels of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL), which are an intermediate astrocyte and neuron filaments, respectively, are clinically useful biomarkers of disease activity and disability in neuromyelitis optica spectrum disorders (NMOSD). METHODS: Levels of GFAP and NfL in serum (sGFAP and sNfL, respectively) and in CSF samples were measured in healthy controls (HCs) (n = 49; 49 serum samples), patients with NMOSD (n = 33; 42 CSF and 102 serum samples), and patients with multiple sclerosis (MS) (n = 49; 53 CSF and 91 serum samples) by ultrasensitive single-molecule array assays. Association of sGFAP and sNfL levels with clinical parameters was determined. RESULTS: < 0.001, respectively). Higher sGFAP/sNfL quotient at relapse differentiated NMOSD from MS with a sensitivity of 73.0% and a specificity of 75.8%. CONCLUSIONS: sGFAP and sNfL are likely to be good biomarkers of disease activity and disability, and the sGFAP/sNfL quotient at relapse is a potential diagnostic marker for NMOSD.

Overview

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000008160

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 40

  1. 10.1084/jem.20050304 · DOI · Paper page
  2. 10.1038/83679 · DOI
  3. 10.1136/jnnp.2008.150698 · DOI
  4. 10.1212/WNL.0b013e3181e2414b · DOI
  5. 10.1177/1352458510379247 · DOI
  6. 10.1136/jnnp.2009.196550 · DOI
  7. 10.1016/0022-510X(95)00152-R · DOI
  8. 10.1212/01.WNL.0000098880.19793.B6 · DOI
  9. 10.1212/01.WNL.0000142988.49341.D1 · DOI
  10. 10.1111/ane.12239 · DOI
  11. 10.1007/s00415-010-5863-2 · DOI
  12. 10.1177/1352458514549397 · DOI
  13. 10.1146/annurev.ne.19.030196.001155 · DOI
  14. 10.1016/j.neuron.2016.05.018 · DOI · Paper page
  15. 10.1038/s41582-018-0058-z · DOI · Paper page
  16. 10.1016/j.ebiom.2015.11.036 · DOI · Paper page
  17. 10.1515/cclm-2015-1195 · DOI · Paper page
  18. 10.1212/WNL.0000000000003154 · DOI
  19. 10.1089/neu.2016.4496 · DOI
  20. 10.1093/brain/awy154 · DOI · Paper page
  21. 10.1212/WNL.0000000000001729 · DOI · Paper page
  22. 10.1177/1352458517732844 · DOI
  23. 10.1016/S1474-4422(18)30285-0 · DOI
  24. 10.1016/j.brainres.2017.05.011 · DOI
  25. 10.1371/journal.pone.0075091 · DOI
  26. 10.1136/annrheumdis-2017-212045 · DOI
  27. 10.1212/WNL.0000000000004932 · DOI
  28. 10.1038/s41598-018-33158-8 · DOI
  29. 10.1523/JNEUROSCI.3742-14.2015 · DOI · Paper page
  30. 10.1093/brain/awm047 · DOI
  31. 10.1016/j.jns.2012.02.012 · DOI
  32. 10.1001/jamaneurol.2016.0039 · DOI
  33. Mariotto S, Farinazzo A, Monaco S, et al. Serum neurofilament light chain in NMOSD and related disorders: comparison according to aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies status. Mult Scler J Exp Transl Clin 2017;3:2055217317743098.
  34. 10.1136/jnnp-2016-313300 · DOI
  35. Disanto G, Adiutori R, Dobson R, et al. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 2016;87:126–129.
  36. 10.1177/1352458517715132 · DOI
  37. 10.1177/1352458518765666 · DOI
  38. 10.1212/WNL.0000000000007032 · DOI
  39. 10.1002/glia.22443 · DOI
  40. 10.3389/fimmu.2018.00217 · DOI

Cited by

Sorted by citations

See all 220

Metadata

Authors
Watanabe, M., Nakamura, Y., Michalak, Z., Isobe, N., Barro, C., Leppert, D., Matsushita, T., Hayashi, F., Yamasaki, R., Kuhle, J., & Kira, J.-I.
Affiliations
  • Kyushu University (JP)
  • From the Departments of Neurology (M.W., Y.N., T.M., F.H., R.Y., J.-i.K.) and Neurological Therapeutics (N.I.), Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; and Neurology (Z.M., C.B., D.L., J.K.), Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Switzerland.
Corresponding author
Kira, Jun-ichi
ORCID
Venue
Neurology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2019-09-24
Volume
93
Issue
13
Pages
e1299-e1311
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
DOI
10.1212/wnl.0000000000008160
OpenAlex
W2970676275
Cited by
220
References
6
Citations by year
2026: 27 · 2025: 39 · 2024: 30 · 2023: 33 · 2022: 32 · 2021: 36 · 2020: 22 · 2019: 1
FWCI
16.75
Type
journal article
Language
en
Open access
closed
Locations
  • Neurology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Fukuoka University
  • Center for Clinical and Translational Research
  • Japan Society for the Promotion of Science (20K20470, 18K07529)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
  • Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
Keywords
neuromyelitis optica spectrum disorder, glial fibrillary acidic protein, neurofilament light chain, serum biomarkers, cerebrospinal fluid biomarkers, disease activity, disability progression, relapse, multiple sclerosis, differential diagnosis
MeSH terms
Adult, Biological Assay, Female, Glial Fibrillary Acidic Protein, Persons with Disabilities, Disabled Persons, Humans, Intermediate Filaments, Male, Middle Aged, Multiple Sclerosis, Neuromyelitis Optica, Biomarkers, Neurofilament Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review